Exploring how hydrogen sulfide protects brain cells in Alzheimer's disease
Neuroprotective actions of cystathionine g-lyase through gasotransmitter hydrogen sulfide signaling
['FUNDING_R01'] · JOHNS HOPKINS UNIVERSITY · NIH-11089418
This study is looking at how a gas called hydrogen sulfide might help protect brain cells from damage caused by Alzheimer's disease, with the hope of finding new ways to treat the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11089418 on ClinicalTrials.gov |
What this research studies
This research investigates the role of hydrogen sulfide (H2S), a gasotransmitter, in protecting brain cells from damage associated with Alzheimer's disease. The study aims to identify the specific signaling pathways that H2S influences in the brain, which could lead to new therapeutic strategies. By understanding how H2S interacts with proteins involved in neuronal function, the research seeks to uncover potential treatments that could mitigate neurodegeneration. The approach involves examining the metabolism of cysteine and its conversion to H2S, which is crucial for brain health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those experiencing early cognitive decline.
Not a fit: Patients with non-neurodegenerative conditions or those not affected by age-related cognitive decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that slow down or prevent the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in using gasotransmitters like hydrogen sulfide for neuroprotection, indicating potential for success in this area.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PAUL, BINDU — JOHNS HOPKINS UNIVERSITY
- Study coordinator: PAUL, BINDU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: age associated disease, age associated disorder, age associated neurodegenerative disease, age associated neurodegenerative disorder